We use cookies for certain features and to improve your experience. See our Cookie Policy and Privacy Policy to learn more

Leafly

Shop legal, local weed.

Open
advertise on Leafly
ShopDeliveryDispensariesDealsStrainsBrandsProductsLeafly PicksCBDDoctorsCannabis 101Social impact
  • Sign in
  • Create account
  • Strains
  • Shop
  • Shop
  • Delivery
  • Deals
  • Dispensaries
  • CBD Stores
  • Brands
  • Products
  • Leafly Picks
  • Learn
  • Cannabis 101
  • News
  • Leafly Learn
  • Science of cannabis
  • Doctors
  • Social impact
  • Lab partners
  • Download the Leafly App
  • Advertise on Leafly
    • Leafly.comUSA flag
    • Leafly.caCanadian flag
  • Help
  1. Home
  2. News
  3. Politics
  4. Removing Cannabidiol Oil From the Controlled Substances Act Will Allow Crucial Access for Patients
  • News
  • Cannabis 101
  • Growing
  • Strains & products
  • CBD
  • Politics
  • Health
  • Lifestyle
  • Science & tech
  • Industry
  • Reports
  • Canada
  • Podcasts
  • Leafly Lists
Politics

Removing Cannabidiol Oil From the Controlled Substances Act Will Allow Crucial Access for Patients

Lisa RoughLast updated July 28, 2020

A major obstacle that states have faced in the fight for medical marijuana has been the Controlled Substances Act, namely that cannabis and all of its related extractions has been categorized as a Schedule I drug. Anything that’s classified as a Schedule I drug means that, according to the federal government, the substance has no medicinal value whatsoever. Patients who rely on CBD oil to manage their debilitating symptoms and conditions would disagree with that claim. Fortunately, one important aspect of the new federal medical marijuana bill called the Compassionate Access, Research Expansion and Respect States Act (or the CARERS Act) is the removal of CBD oil from the Controlled Substance Act.

There has been a recent change of heart from some of the more conservative states in the past few years, as we’ve watched Alabama, Florida, Georgia, Kentucky, Iowa, Mississippi, Missouri, North and South Carolinas, Tennessee, Utah, Virginia, and Wisconsin all legalize the limited use of cannabidiol oils for certain patients, usually those suffering from seizure disorders. These laws are passed with the best of intentions, as many of the seizure disorders targeted by the legislation are suffered by children. However, as these are often conservative states with little to no background on the ins and outs of legalizing cannabis in any form, these laws are nothing more than words on a page.

Yes, the laws were passed, but they offer no means of access for patients. States have no infrastructure for the production, processing, and manufacturing of cannabis oils, and the laws do not allow for personal cultivation. The only way for a patient to acquire cannabis oil is to travel to a legal state (such as Colorado or Washington) and risk federal prosecution to bring the product back to their home state. Once they run out? The cycle begins again.

If the CARERS Act is passed, patients will no longer have to break federal laws to acquire their medicine. Not only that, but states will no longer have their hands tied when it comes to providing this medicine. Removing CBD oil completely from the definition of “marijuana” as it is defined by the U.S. government means that even states without medical marijuana laws could allow access for patients who so desperately need it.

That’s a win in my book.

Throw your support behind the CARERS Act by doing one (or all) of the following:

  • Find your representative or call your senator
  • Call (202) 225-3131 — House members can be reached through the Capitol switchboard
  • Learn more about reforming marijuana laws through the Drug Policy Alliance
  • Write a letter to your representative using the below language as a guideline:

Dear Senator _______,

I am writing to urge you to support the CARERS Act recently introduced by Senators Gillibrand, Booker, and Paul. Removing cannabis as a Schedule I drug opens the doors for doctors to legally prescribe medical marijuana to those in need of its benefits. It would safeguard the freedom of patients to choose a method of treatment that improves their quality of life and eliminate the fear associated with its criminalization. Federal restrictions on cannabis have obstructed valuable research that would shed light on marijuana’s benefits and risks, knowledge we owe to doctors and patients hoping to make informed medical decisions. It is imperative that we reconcile discrepancies between federal and state marijuana laws, so I ask that you please support the CARERS Act for your constituents, for patients, and for advocates across the nation. Thank you for your time.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • See all dispensaries
See all dispensaries
cannabidiolcarers actcbdControlled Substances Actlegalizationlegislationmedical marijuanaseizures
Lisa Rough
Lisa Rough
Lisa is a former associate editor at Leafly, where she specialized in legislative cannabis policy and industry topics.
View Lisa Rough's articles

The latest in Politics

  • How US import tariffs are impacting cannabis prices and products image
    How US import tariffs are impacting cannabis prices and products
    Leafly Staff
  • Ohioans must activate to defend cannabis freedoms from lawmakers image
    Ohioans must activate to defend cannabis freedoms from lawmakers
    David Downs
  • Montanans must activate to protect legalization in 2025 image
    Montanans must activate to protect legalization in 2025
    David Downs
  • Analysis: Don’t hold your breath for legalization under Trump 2.0 image
    Analysis: Don’t hold your breath for legalization under Trump 2.0
    David Downs
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

Something went wrong, please try again.

By providing us with your email address, you agree to Leafly’s Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App StoreDownload Leafly Marijuana Reviews on Google Play

Business Solutions
  • List your store
  • List your CBD store
  • List your brand
  • List your practice
  • Business log in

About Leafly
  • About us
  • Careers
  • Newsroom
  • Investor relations
  • Contact us
  • FAQs
  • Accessibility

Dispensaries in
  • Los Angeles
  • Seattle
  • Portland
  • San Francisco
  • Toronto
  • Detroit

Privacy & Terms
  • Terms of use
  • Commercial terms of use
  • Privacy policy
  • Do not sell my personal information

* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2025 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.